CA-TULA-TECHNOLOGY
10.11.2021 10:02:08 CET | Business Wire | Press release
As world leaders gather in Glasgow for the 26th United Nations Climate Change Conference of the Parties (COP26), there is once again a push for strategies to reach net zero by 2050. With the transportation sector currently the fastest growing contributor to climate change and now accounting for almost a quarter of emissions, Tula Technology, Inc., a leader in propulsion efficiency, has accelerated the pace of innovation to reduce the environmental impact of passenger and commercial vehicles through its Dynamic Skip Fire (DSF®) and Dynamic Motor Drive (DMD™) technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005156/en/
“To reach net zero, OEMs are faced with meeting increasingly stringent emissions reductions standards,” said R. Scott Bailey, president and CEO of Tula Technology. “Tula has developed technologies that make it possible to achieve these mandates in a cost-effective manner. Whether we’re working with partners to reduce emissions in internal combustion engines or offering solutions to make electric vehicles more efficient, our team is committed to improving propulsion efficiency for a cleaner environment.”
The Tula Track Record of Innovation
- Using patented algorithms, DSF® chooses to skip or fire individual cylinders dynamically to meet an engine’s torque demands, enabling near-peak engine efficiency for a cleaner-burning, more fuel-efficient vehicle.
- DMD™ mitigates efficiency losses in electric motors while significantly reducing reliance on rare-earth materials. DMD’s application to electric vehicles (EVs) has the potential to increase range while using less energy. DMD is a cost-effective, software-driven solution. Without the need for rare earth materials , potential supply chain challenges and escalating costs can be avoided.
- A recent study of Tula’s DSF in a Class 8 truck powered by a Cummins X15 HD engine showed a 74 percent reduction in nitrogen oxides (NOX ) and a 5 percent reduction in carbon dioxide (CO2 ) . To demonstrate DSF in action, Tula recently released a “virtual test drive” video.
- FEV, an international engineering partner to the auto industry, joined Tula to evaluate Tula’s DSF for mild hybrid diesel vehicles and found an additional 11% of CO2 was eliminated compared to industry-leading hybrid powertrains. The CO2 reduction can be achieved at a cost of about $235 (€200) per vehicle. For manufacturers of light duty commercial vehicles, this technology offers a compelling and cost-effective solution to achieve challenging Euro 7 emission standards expected to go into effect by 2026 for all new vehicles in Europe.
- Tula and Jacobs Vehicle Systems signed an agreement and are working together to integrate DSF and Jacobs Cylinder Deactivation technology . Independent laboratory testing has demonstrated that Jacobs CDA hardware and Tula’s DSF achieve greater emission reductions when combined.
- Tula is partnering with Chinese vehicle equipment manufacturer E-Quality Tec, Inc. to embed DSF into E-Quality’s controller . Rapidly deploying fully integrated technology will enable medium and heavy-duty diesel vehicle manufacturers in China to aggressively target simultaneous reductions in both CO2 and NOX for CN Stage VI, China’s emission standard for heavy-duty vehicles.
- More than 1.5 million General Motors passenger vehicles are on the road in the U.S. utilizing DSF, each one saving roughly one ton of CO2 emissions each year, using the same cost-effective technology being deployed in commercial diesel and hybrid vehicles.
- Tula’s talented team members are on the cutting edge of automotive engineering, and recently were awarded their 200th global patent and have 378 patents issued or pending .
Tula is driven to improve efficiency across all manner of transportation and reduce emissions without sacrificing performance or comfort. We support immediate action on climate and clean air regulations to promote a sustainable future powered by innovation.
About Tula Technology, Inc.
Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including gasoline-powered, diesel, alternative fuel, hybrid, and electric vehicles. Tula’s culture of innovation has resulted in breakthrough technology and a robust global patent portfolio of more than 378 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Qualcomm Announces Quarterly Cash Dividend17.4.2026 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on June 25, 2026, to stockholders of record at the close of business on June 4, 2026. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 202617.4.2026 13:00:00 CEST | Press release
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary me
BlackBerry, JVCKENWOOD and SK Telecom Join Sisvel POS Patent Pool as Licensors17.4.2026 09:04:00 CEST | Press release
The new Sisvel Point of Sale (POS) patent pool, announced on 1 April, has added three new licensors in the last two weeks. BlackBerry, JVCKENWOOD and SK Telecom have joined founding licensors Huawei, LG Electronics and Nokia in making their patents available for license through the programme. Sisvel POS covers 2G, 3G, 4G and 5G technologies. It is the first joint licensing programme to address point of sale devices – a category of product that has leveraged cellular connectivity to transform customer payment processing. Participating patent owners make their relevant standards essential patents (SEPs) available on FRAND terms, simplifying access to essential IP rights for POS device makers. Early participation incentives for licensors are available until mid-May. Parties interested in joining the pool are encouraged to contact Sisvel as soon as possible. “BlackBerry, JVCKENWOOD and SK Telecom are first-rate cellular innovators. I am pleased they have chosen to become part of Sisvel POS
Adtran wins two FTTH Innovation Awards for AI‑driven network operations and home Wi‑Fi17.4.2026 09:00:00 CEST | Press release
News summary: Mosaic One Clarity recognized for applying explainable AI to shift fiber operations from reactive troubleshooting to proactive assurance Adtran’s SDG 8000 and 9000 Series honored for delivering multigigabit, whole‑property Wi‑Fi with unified software and cloud management Awards highlight Adtran’s focus on innovation that helps service providers scale fiber efficiently while improving customer experience Adtran today announced two wins at the FTTH Innovation Awards 2026, recognizing its leadership across in-home connectivity and AI‑driven network operations. The company received awards in the categories for ‘Active infrastructure – home network’ and ‘Artificial intelligence (AI), machine learning and other software.’ Organized by FTTH Council Europe, the annual awards honor technologies that advance fiber deployment while improving scalability, operational efficiency and user experience. Voted by FTTH Conference 2026 speakers, the results reflect peer recognition for Mosai
Samsung Bioepis Highlights Consistent Efficacy of SB16 (OBODENCE®; Denosumab) Across Osteoporosis Patient Subgroups at WCO-IOF-ESCEO 202617.4.2026 08:00:00 CEST | Press release
- Subgroup analysis from Phase 3 study demonstrates consistent efficacy of SB16 across key patient populations - Results reinforce the totality-of-evidence supporting SB16 biosimilarity Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE®1), a biosimilar to Prolia2 (denosumab) across patient subgroups compared to the reference denosumab. The data will be presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2026 in Prague from April 16 to 19. “Consistent efficacy across patient subgroups is critical in reinforcing physician confidence and advancing treatment accessibility for patients with osteoporosis,” said Jeehoon Ghil, Vice President and Medical & Lifecycle Safety Team Leader at Samsung Bioepis. “Such data contribute to the robustness of the overall biosimilarity assessment and support the clinical confidence in our denosumab biosimilar.” SB16 was evaluate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
